Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Patients’ characteristics, clinical manifestations and laboratory results in patients with Raynaud’s phenomenon

From: Application of the 2013 ACR/EULAR classification criteria for systemic sclerosis to patients with Raynaud’s phenomenon

Variables Patients with Raynaud’s phenomenon (N = 64)
Characteristics  
  Age (years old) 50.9 ± 14.4
  Sex, female (N (%)) 58 (90.6)
  Raynaud’s phenomenon duration (years) 5.3 ± 7.7
Newly classified to systemic sclerosis by the 2013 ACR/EULAR classification criteria (N (%)) 17 (26.5)
Autoimmune disease accompanied (N (%)) 33 (51.6)
  Sjögren syndrome 15 (23.4)
  Systemic lupus erythematosus 8 (12.5)
  Mixed connective tissue disease 5 (7.8)
  Rheumatoid arthritis 3 (4.7)
  Inflammatory myopathy 2 (3.1)
Clinical manifestations (N (%))  
  Scleroderma (proximal) 0 (0)
  Puffy finger 34 (53.1)
  Sclerodactyly 7 (10.9)
  Digital tip ulcer 2 (3.1)
  Fingertip pitting scar 0 (0)
  Telangiectasia 7 (10.9)
  Abnormal nailfold capillaries 46 (71.8)
  Pulmonary arterial hypertension 1 (1.6)
  Interstitial lung disease 5 (7.8)
Autoantibodies (N (%))  
  Antinuclear antibody (centromere) 19 (29.7)
  Anti-centromere antibody 22 (34.4)
  Anti-Scl-70 antibody 2 (3.1)
  1. Values are expressed as N (%) or mean ± standard deviation. ACR, American College of Rheumatology; EULAR, The European League Against Rheumatism.